Nedan finns en sammanställning av dokumentation för Apidra.
Studier på typ 1-diabetes
Dreyer et al. Efficacy and Safety of Insulin Glulisine in Patients With Type 1 Diabetes, Hormon Metab Res 2005;37:702-707
Garg et al. Optimized Basal-Bolus Insulin Regimens in Type 1 Diabetes: Insulin Glulisine Versus Regular Human Insulin in Combination With Basal Insulin Glargine, Endocr Practice 2005:11;11-17
Hoogma et al. Safety of Insulin Glulisine when Given by Continuous Subcutaneous Infusion Using an External Pump in Patients with Type 1 Diabetes Horm Metab Res 2006; 38: 429±433
Danne et al. Pharmacokinetics, Prandial Glucose Control, and Safety of Insulin Glulisine in Children and Adolescents With Type 1 Diabetes. Diabetes Care, Vol 28, No 9, September 2005
Studier på typ 2-diabetes
Dailey et al. InsulinGlulisine Provides Improved Glycemic Control in Patients With Type 2-Diabetes, Diabetes Care 2004;27:2363-2368
Farmakokinetik
Becker R et al. Insulin Glulisine, a New Rapid Acting Insulin Analogue, Displays A Rapid Time-Action Profile in Obese Non-Diabetic Subjects, Exp Clin Endocrinol Diabetes 2005;113:435–443
Heise et al. Insulin glulisine: a faster onset of action compared with insulin lispro, Diabetes, Obesity and Metabolism, 9, 2007, 746–753
In vivo studier
Henninge et al. Insulin Receptor Signaling Characteristics In Vivo, Diabetes 2005:54;361-366
Rakatzi et al. A Novel Insulin Analog With Unique Properties, Diabetes 2003:52;2227-2238
Rakatzi et al. [LysB3, GluB29] insulin: a novel insulin analog with enhanced–cell protective action, Biochemical and Biophysical Research Communications 2003:310;852-859